Recursion Pharmaceuticals, Inc. RXRX Free cash flow
Free cash flow at other companies
Other financials
Where this comes from
Calculated from Recursion Pharmaceuticals, Inc.’s reported figures.
The official record: Recursion Pharmaceuticals, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Recursion Pharmaceuticals, Inc.'s free cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Recursion Pharmaceuticals, Inc.'s free cash flow?
- Recursion Pharmaceuticals, Inc. (RXRX) reported free cash flow of -$81.36M in Q1 2026.
- How has Recursion Pharmaceuticals, Inc.'s free cash flow changed year-over-year?
- Recursion Pharmaceuticals, Inc.'s free cash flow increased by 39.2% year-over-year, from -$133.79M to -$81.36M.
- What is the long-term trend for Recursion Pharmaceuticals, Inc.'s free cash flow?
- Over 4 years (2021 to 2025), Recursion Pharmaceuticals, Inc.'s free cash flow has grown at a 17.5% compound annual growth rate (CAGR), from -$198.41M to -$378.28M.
- What does free cash flow mean?
- Free cash flow represents the cash generated by a company after accounting for cash outflows to support operations and maintain or expand its capital asset base. It serves as a critical indicator of a company's ability to fund organic growth, pay down debt, or return capital to shareholders without relying on external financing.